Recombinant human endostatin combined with TP regimen as postoperative adjuvant treatment for non-small-cell lung cancer

Objective To evaluate the mid-term and long-term efficacy of recombinant human endostatin (rh-endostatin, Endostar) in combination with docetaxel and carboplatin (TP) regimen as a postoperative adjuvant treatment for non-small-cell lung cancer (NSCLC). Methods A randomized controlled trial was condu...

Full description

Saved in:
Bibliographic Details
Published inJie fang jun yi xue za zhi Vol. 37; no. 1; pp. 49 - 53
Main Authors Yang, Y-Z, Pan, L-K, Qi, D-L, Xin, L, Cui, Y, An, G-Y
Format Journal Article
LanguageChinese
Published 01.01.2012
Subjects
Adjuvants
Carboplatin
Cell survival
Chemotherapy
Clinical trials
Differentiation
endostatin
Endothelial cells
Lung cancer
Lymph nodes
Tumors
Online AccessGet full text

Cover

More Information
Summary:Objective To evaluate the mid-term and long-term efficacy of recombinant human endostatin (rh-endostatin, Endostar) in combination with docetaxel and carboplatin (TP) regimen as a postoperative adjuvant treatment for non-small-cell lung cancer (NSCLC). Methods A randomized controlled trial was conducted in 76 patients who were admitted from October 2006 to July 2008. These patients were diagnosed with NSCLC and experienced complete excision. They were randomly divided into two groups (n=38): Endostar plus TP regimen was adopted for the treatment group, while only the TP regimen was used for the control group. After 40 months of postoperative followup, the difference in disease-free survival (DFS) and overall survival (OS) between the two groups was evaluated, and the number of circulating endothelial cells (CECs) and tumor microvessel density (MVD) were measured. Results DFS was significantly longer in the treatment group than that in the control group (39.4 months versus 27.6 months, P<0.05). The three-year
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 23
ObjectType-Feature-1
ISSN:0577-7402